Molecular Basis of PTH Overexpression

Principles of Bone Biology: Volume 1-2, Third Edition

Volumn , Issue , 2008, Pages 1311-1326

  Hendy, Geoffrey N ^a   Arnold, Andrew ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954893409     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00073-2     Document Type: Chapter

References (165)

1. S.K. Agarwal, E. Schrock, M.B. Kester, A.L. Burns, C.S. Heffess, T. Ried and S.J. Marx (1998) Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet. Cytogenet. 106 30-36.
2. S.K. Agarwal, S.C. Guru, C. Heppner, M.R. Erdos, R.M. Collins, S.Y. Park, S. Saggar, S.C. Chandrasekharappa, F.S. Collins, A.M. Spiegel, S.J. Marx and A.L. Burns (1999) Menin interacts with the AP-1 transcription factor JunD and represses JunD-activated transcription. Cell 96 143-152.
3. S.K. Agarwal, E.A. Novotny, J.S. Crabtree, J.B. Weitzman, M. Yaniv, A.L. Burns, S.C. Chandrasekharappa, F.S. Collins, A.M. Spiegel and S.J. Marx (2003) Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc. Natl. Acad. Sci. USA 100 10770-10775.
4. A. Arnold (1993) Genetic basis of endocrine disease 5: Molecular genetics of parathyroid gland neoplasia. J. Clin. Endocrinol. Metab. 77 1108-1112.
5. A. Arnold and H.G. Kim (1989) Clonal loss of one chromosome 11 in a parathyroid adenoma. J. Clin. Endocrinol. Metab. 69 496-499.
6. A. Arnold and A. Papanikolaou (2005) Biology of neoplasia—cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 23 4215-4224.
7. A. Arnold, C.E. Staunton, H.G. Kim, R.D. Gaz and H.M. Kronenberg (1988) Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N. Engl. J. Med. 318 658-662.
8. A. Arnold, H.G. Kim, R.D. Gaz, R.L. Eddy, Y. Fukushima, M.G. Byers, T.B. Shows and H.M. Kronenberg (1989) Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J. Clin. Invest. 83 2034-2040.
9. A. Arnold, M. Brown., P. Urena, R.D. Gaz, E. Sarfati and T. Drueke (1995) Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J. Clin. Invest. 95 2047-2053.
10. K. Balogh, K. Racz, A. Patocs and L. Hunyady (2006) Menin and its interacting proteins: Elucidation of menin function. Trends Endocrinol. Metab. 17 357-364.
11. R. Bernards (1999) CDK-independent activities of D type cyclins. Biochem. Biophys. Acta 1424 M17-m22.
12. P. Bertolino, W.M. Tong, D. Galendo, Z.Q. Wang and C.X. Zhang (2003) Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol. Endocrinol. 17 1880-1892.
13. P. Bjorkland, G. Akerstrom and G. Westin (2007) Accumulation of nonphosphorylated β-catenin and c-myc in pimary and uremic secondary hyperparathyroid tumors. J. Clin. Endocrinol. Metab. 92 338-344.
14. W.C. Black III and J.R. Utley (1968) The differential diagnosis of parathyroid adenoma and chief cell hyperplasia. Am. J. Clin. Pathol. 49 761-775.
15. K.J. Bradley, M.R. Hobbs, I.D. Buley, J.D. Carpten, B.M. Cavaco, J.E. Fares, P. Laidler, S. Manek, C.M. Robbins, I.S. Salti, N.W. Thompson, C.E. Jackson and R.V. Thakker (2005) Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J. Intern. Med. 257 18-26.
16. K.J. Bradley, M.R. Bowl, S.E. Williams, B.N. Ahmad, C.J. Partridge, A.L. Patmanidi, A.M. Kennedy, N.Y. Loh and R.V. Thakker (2007) Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 26 1213-1221.
17. S.B. Brown, T.T. Brierley, N. Palanisamy, I.B. Salusky, W. Goodman, M.L. Brandi, T.B. Drueke, E. Sarfati, P. Urena, R.S.K. Chaganti, J.W. Pike and A. Arnold (2000) Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. J. Clin. Endocrinol. Metab. 85 868-872.
18. C. Bystrom, C. Larsson, C. Blomberg, K. Sandelin, U. Falkmer, B. Skogseid, K. Oberg, S. Werner and M. Nordenskjold (1990) Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc. Natl. Acad. Sci. USA 87 1968-1972.
19. L. Canaff and G.N. Hendy (2002) Human calcium-sensing receptor gene: Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1, 25-dihydroxyvitamin D. J. Biol. Chem. 277 30337-30350.
20. L. Canaff, X. Zhou, J.F. Vanbellinghen, L. Vautour, D. Goltzman and G.N. Hendy (2006) Identification and functional characterization of novel mutations in the multiple endocrine neoplasia type 1 (MEN1) gene in three families. Program & Abstracts 88th Ann. Meet. Endo. Soc. P2-p387.
21. T. Carling, Y. Imanishi, R.D. Gaz and A. Arnold (1999) Analysis of the RAD54 gene on chromosome 1p as a potential tumor-suppressor gene in parathyroid adenomas. Int. J. Cancer 83 80-82.
22. T. Carling, Y. Imanishi, R.D. Gaz and A. Arnold (1999) RAD51 as a candidate parathyroid tumor suppressor gene on chromosome 15q: Absence of somatic mutations. Clin. Endocrinol. 51 403-407.
23. T. Carling, E. Szabo, M. Bai, P. Ridefelt, G. Westin, P. Gustavsson, S. Trivedi, P. Hellman, E.M. Brown, B. Dahl and J. Rastad (2000) Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J. Clin. Endocrinol. Metab. 85 2042-2047.
24. J.D. Carpten, C.M. Robbins, A. Villablanca, L. Forsberg, S. Presciuttini, J. Bailey-Wilson, W.F. Simonds, E.M. Gillanders, A.M. Kennedy, J.D. Chen, S.K. Agarwal, R. Sood, M.P. Jones, T.Y. Moses, C. Haven, D. Petillo, P.D. Leotlela, B. Harding, D. Cameron, A.A. Pannett, A. Hoog, H. Heath III, L.A. James-Newton, B. Robinson, R.J. Zarbo, B.M. Cavaco, W. Wassif, N.D. Perrier, I.B. Rosen, U. Kristofferson, P.D. Turnpenny, L.O. Farnebo, G.M. Besser, C.E. Jackson, H. Morreau, J.M. Trent, R.V. Thakker, S.J. Marx, B.T. Teh, C. Larsson and M.R. Hobbs (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32 676-680.
25. C.A. Carrasco, A.A. Gonzalez, C.A. Carvajal, C. Campusano, E. Oestreicher, E. Arteaga, N. Wohlik and C.E. Fardella (2004) Novel intronic mutation of MEN1 gene causing familial isolated primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 89 4124-4129.
26. Castleman, B., and Roth, S. I. (1978). Tumors of the parathyroid glands. In “Atlas of Tumor Pathology” (W. H. Hartman, ed.). Armed Forces Institute of Pathology, Washington, DC. second series, fascicle 14.
27. F. Cetani, A. Pinchera, E. Pardi, L. Cianferotti, E. Vignali, E. Picone, P. Miccoli, P. Viacava and C. Marcocci (1999) No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. J. Bone Miner. Res. 14 878-882.
28. F. Cetani, E. Pardi, S. Borsari, P. Viacava, G. Dipollina, L. Cianferotti, E. Ambrogini, E. Gazzerro, G. Colussi, P. Berti, P. Miccoli, A. Pinchera and C. Marcocci (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: Germline and somatic mutations in familial and sporadic parathyroid tumors. J. Clin. Endocrinol. Metab. 89 5583-5591.
29. F. Cetani, E. Ambrogini, P. Viacava, E. Pardi, G. Fanelli, A. Giuseppe, A.G. Naccarato, S. Borsari, M. Lemmi, P. Berti, P. Miccoli, A. Pinchera and C. Marcocci (2007) Should parafibromin staining replace HRPT2 gene analysis as an additional tool of histologic diagnosis of parathyroid carcinoma? Eur, J, Endocrinol. 156 547-554.
30. S.C. Chandrasekharappa, S.C. Guru, P. Manickam, S.E. Olufemi, F.S. Collins, M.R. Emmert-Buck, L.V. Debelenko, Z. Zhuang, I.A. Lubensky, L.A. Liotta, J.S. Crabtree, Y. Wang, B.A. Roe, J. Weisemann, M.S. Boguski, S.K. Agarwal, M.B. Kester, Y.S. Kim, C. Heppner, Q. Dong, A.M. Spiegel, A.L. Burns and S.J. Marx (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 404-407.
31. J.D. Chen, C. Morrison, C. Zhang, K. Kahnoski, J.D. Carpten and B.T. Teh (2003) Hyperparathyroidism-jaw tumour syndrome. J. Int. Med. 253 634-642.
32. N. Chikatsu, S. Fukumoto, Y. Takeuchi, M. Suzawa, T. Obara, T. Matsumoto and T. Fujita (2000) Cloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas. J. Biol. Chem. 275 7553-7557.
33. J. Costa-Guda and A. Arnold (2007) Absence of stabilizing mutations of β-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 92 1564-1566.
34. J.S. Crabtree, P.C. Scacheri, J.M. Ward, L. Garrett-Beal, M.R. Emmert-Buck, K.A. Edgemon, D. Lorang, S.K. Libutti, S.C. Chandrasekharappa, S.J. Marx, A.M. Spiegel and F.S. Collins (2001) A mouse model of multiple endocrine neoplasia type 1 develops multiple endocrine tumors. Proc. Natl. Acad. Sci. USA 98 1118-1123.
35. V.L. Cryns, M.P. Rubio, A.D. Thor, D.N. Louis and A. Arnold (1994) p53 abnormalities in human parathyroid carcinoma. J. Clin. Endocrinol. Metab. 78 1320-1324.
36. V.L. Cryns, A. Thor, H.J. Xu, S.X. Hu, M.E. Wierman, A.L. Vickery, W.F. Benedict and A. Arnold (1994) Loss of the retinoblastoma tumor suppressor gene in parathyroid carcinoma. N. Engl. J. Med. 330 757-761.
37. V.L. Cryns, S.M. Yi, H. Tahara, R.D. Gaz and A. Arnold (1995) Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosom. Cancer 13 9-17.
38. S. Degenhardt, A. Toell, W. Weidmann, C. Dotzenrath and K.D. Spindler (1998) Point mutations of the human parathyroid calcium receptor gene are not responsible for non-suppressible renal hyperparathyroidism. Kidney Int. 53 556-561.
39. C. Dotzenrath, B.T. Teh, F. Farnebo, K. Cupisti, A. Svensson, A. Toell, P. Goretzki and C. Larsson (1996) Allelic loss of the retinoblastoma tumor suppressor gene: A marker for aggressive parathyroid tumors? J. Clin. Endocrinol. Metab. 81 3194-3196.
40. K.M.A. Dreijerink, J.W.M. Hoppener, H.T.M. Timmers and C.J.M. Lips (2006) Mechanisms of disease: Multiple endocrine neoplasia type 1—relation to chromatin modifications and transcriptional regulation. Nat. Clin. Pract. Endocrinol. Metab. 2 562-570.
41. L. D'Souza-Li, B. Yang, L. Canaff, M. Bai, D.A. Hanley, M. Bastepe, S.R. Salisbury, E.M. Brown, D.E.C. Cole and G.N. Hendy (2002) Identification and functional characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. J. Clin. Endocrinol. Metab. 87 1309-1318.
42. T. Dwight, A.E. Nelson, G. Theodosopoulos, A.L. Richardson, D.L. Learoyd, J. Philips, L. Delbridge, J. Zedenius, B.T. Teh, C. Larsson, D.J. Marsh and B.G. Robinson (2002) Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. Am. J. Pathol. 161 1299-1306.
43. C. Eng, D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R.F. Gagel, H.K. van Amstel, C.J. Lips, I. Nishisho, S.I. Takai, D.J. Marsh, B.G. Robinson, K. Frank-Raue, F. Raue, F. Xue, W.W. Noll, C. Romei, F. Pacini, M. Fink, B. Niederle, J. Zedenius, M. Nordenskjöld, P. Komminoth, G.N. Hendy and L.M. Mulligan (1996) The relationship between speific RET proto-oncogene mutations and disease phenotype in multiple neoplasia type 2. JAMA 276 1575-1579.
44. European Consortium on MEN1 (1997) Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum. Mol. Genet. 6 1177-1183.
45. M.E. Ewen and J. Lamb (2004) The activities of cyclin D1 that drive tumorigenesis. Trends Mol. Med. 10 158-162.
46. A. Falchetti, A.E. Bale, A. Amorosi, C. Bordi, P. Cicchi, S. Bandini, S.J. Marx and M.L. Brandi (1993) Progression of uremic hyperparathyroidism involves allelic loss on chromosome 11. J. Clin. Endocrinol. Metab. 76 139-144.
47. F. Farnebo, U. Enberg, L. Grimelius, M. Backdahl, M. Schalling, C. Larsson and L.O. Farnebo (1997) Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 82 3481-3486.
48. F. Farnebo, A. Hoog, K. Sandelin, C. Larsson and L.O. Farnebo (1998) Decreased expression of calcium-sensing receptor messenger ribonucleic acids in parathyroid adenomas. Surgery 124 1094-1098.
49. F. Farnebo, S. Kytola, B.T. Teh, T. Dwight, F.K. Wong, A. Hoog, M. Elvius, W.S. Wassif, N.W. Thompson, L.O. Farnebo, K. Sandelin and C. Larsson (1999) Alternative genetic pathways in parathyroid tumorigenesis. J. Clin. Endocrinol. Metab. 84 3775-3780.
50. D.S. Franklin, V.L. Godfrey, D.A. O’ Brien, C. Deng and Y. Xiong (2005) Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct issue specificity. Mol. Cell. Biol. 20 6147-6156.
51. E. Friedman, K. Sakaguchi, A.E. Bale, A. Falchetti, E. Streeten, M.B. Zimering, L.S. Weinstein, W.O. McBride, Y. Nakamura, M-L. Brandi, J.A. Norton, G.D. Aurbach, A.M. Spiegel and S.J. Marx (1989) Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N. Engl. J. Med. 321 213-218.
52. E. Friedman, A.E. Bale, S.J. Marx, J.A. Norton, A. Arnold, T. Tu, G.D. Aurbach and A.M. Spiegel (1990) Genetic abnormalities in sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 71 293-297.
53. M. Fu, C. Wang, Z. Li, T. Sakamaki and R.G. Pestell (2004) Cyclin D1: Normal and abnormal functions. Endocrinology 145 5439-5447.
54. S.C. Galbraith and L.D. Quarles (1994) Tertiary hyperparathyroidism and refractory secondary hyperparathyroidism. J.P. Bilezikian, R. Marcus, M.A. Levine (Eds) The Parathyroids New York: Raven Press 159-163.
55. A.J. Gill, A. Clarkson, O. Gimm, J. Keil, H. Dralle, V.M. Howell and D.J. Marsh (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am. J. Surg. Pathol. 30 1140-1149.
56. J. Gogusev, P. Duchambon, B. Hory, M. Giovannini, Y. Goureau, E. Sarfati and T. Drueke (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51 328-336.
57. V. Guarnieri, A. Scillitani, L.A. Muscarella, C. Battista, N. Bonfitto, M. Bisceglia, S. Minisola, M.L. Mascia, L. D'Agruma and D.E.C. Cole (2006) Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: Implications for cancer surveillance. J. Clin. Endocrinol. Metab. 91 2827-2832.
58. S.C. Guru, P.K. Goldsmith, A.L. Burns, S.J. Marx, A.M. Spiegel, F.C. Collins and S.C. Chandrasekharappa (1998) Menin, the product of the MEN1 gene, is a nuclear protein. Proc. Natl. Acad. Sci. USA 95 1630-1634.
59. M.A. Hahn and D.J. Marsh (2005) Identification of a functional bipartite nuclear localization signal in the tumor suppressor paraafibromin. Oncogene 24 6241-6248.
60. J.P. Hakim and M.A. Levine (1994) Absence of p53 point mutations in parathyroid adenoma and carcinoma. J. Clin. Endocrinol. Metab. 78 103-106.
61. G.N. Hendy, H.M. Kronenberg, J.T. Potts Jr. and A. Rich (1981) Nucleotide sequence of cloned cDNAs encoding human pre-proparathyroid hormone. Proc. Natl. Acad. Sci. USA 78 7365-7369.
62. G.N. Hendy, L. D'Souza-Li, B. Yang, L. Canaff and D.E.C. Cole (2000) Mutation update. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum. Mutat. 16 281-296.
63. G.N. Hendy, H. Kaji, H. Sowa, J.J. Lebrun and L. Canaff (2005) Menin and TGF-β superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm. Metab. Res. 37 375-379.
64. M.R. Hobbs, I.B. Rosen and C.E. Jackson (2002) Revised 14, 7-cM locus for the hyperparathyroidism-jaw tumor syndrome gene, HRPT2. Am. J. Hum. Genet. 70 1376-1377.
65. Y. Hosokawa and A. Arnold (1998) Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele specific expression. Genes Chromosom. Cancer 22 66-71.
66. Y. Hosokawa, M.R. Pollak, E.M. Brown and A. Arnold (1995) Mutational analysis of the extracellular Ca2+-sensing receptor gene in human parathyroid tumors. J. Clin. Endocrinol. Metab. 80 3107-3110.
67. V.M. Howell, C.J. Haven, K. Kahnoski, S.K. Khoo, D. Petillo, J. Chen, G.J. Fleuren, B.G. Robinson, L.W. Delbridge, J. Philips, A.E. Nelson, U. Krause, K. Hammje, H. Dralle, C. Hoang-Vu, O. Gimm, D.J. Marsh, H. Morreau and B.T. Teh (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Mol. Genet. 40 657-663.
68. E. Hsi, L.R. Zukerberg, W.I. Yang and A. Arnold (1996) Cyclin D1 (PRAD1) expression in parathyroid adenomas: an immunohistochemical study. J. Clin. Endocrinol. Metab. 81 1736-1739.
69. C.M. Hughes, O. Rozenblatt-Rosen, T.A. Milne, T.D. Copeland, S.S. Levine, J.C. Lee, D.N. Hayes, K.S. Shanmugam, A. Bhattacharjee, C.A. Biondi, G.F. Kay, N.K. Hayward, J.L. Hess and M. Meyerson (2004) Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 13 587-597.
70. N. Hussein, H. Casses, S. Fontaniere, A.M. Morera, M.J. Asensio, S. Bakeli, J.L. Lu, I. Coste, N. Di Clemente, P. Bertolino and C.X. Zhang (2007) Reconstituted expression of menin in Men1-deficient mouse Leydig tumour cells induces cell cycle arrest and apoptosis. Eur. J. Cancer 43 402-414.
71. S. Ikeda, Y. Ishizaki, Y. Shimizu, M. Fujimori, Y. Ojima, M. Okajima, K. Sugino and T. Asahara (2002) Immunochamistry of cyclin D1 and β-catenin, and mutational analysis of exon 3 of β-catenin gene in parathyroid adenomas. Int. J. Oncol. 20 463-466.
72. H. Imanishi, I.B. Tahara, W.G. Salusky, R.D. Goodman, M. Gaz, L. Brandi, E. Sarfati, T.B. Drueke, A.P. Smith, K. Yoshimoto and A. Arnold (1997) Distinct molecular pathogenesis in different categories of benign hyperparathyroidism. J. Bone Miner. Res. 12(Suppl. 1), S180.
73. Y. Imanishi, H. Tahara, I. Salusky, W. Goodman, M.L. Brandi, B. Drueke, E. Sarfati, P. Urena and A. Arnold (1999) MEN1 gene mutations in refractory hyperparathyroidism of uremia. J. Bone Miner. Res. 14(Suppl. 1), S446.
74. Y. Imanishi, N. Palanisamy, H. Tahara, A. Vickery, V.L. Cryns, R.D. Gaz, D. Shoback, O. Clark, J. Monchik, M. Wierman, A. Hollenberg, K. Tojo, R.S.K. Chaganti and A. Arnold (1999) Molecular pathogenetic analysis of parathyroid carcinoma. J. Bone Miner. Res. 14(Suppl. 1), S421.
75. Y. Imanishi, Y. Hosokawa, K. Yoshimoto, E. Schipani, S. Mallya, A. Papanikolaou, O. Kifor, T. Tokura, M. Sablosky, F. Ledgard, G. Gronowicz, T.C. Wang, E.V. Schmidt, C. Hall, E.M. Brown, R. Bronson and A. Arnold (2001) Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J. Clin. Invest. 107 1093-1102.
76. C.E. Jackson, R.A. Norum, S.B. Boyd, G.B. Talpos, S.D. Wilson, R.T. Taggart and L.E. Mallette (1990) Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: A clinically and genetically distinct syndrome. Surgery 108 1006-1012.
77. N. Janicic, E. Soliman, Z. Pausova, M.F. Seldin, M. Riviere, J. Szpirer, C. Szpirer and G.N. Hendy (1995) Mapping of the calcium-sensing receptor to human chromosome 3q13.3–21 by fluorescence in situ hybridization, and localization to rat chromosome 11 and mouse chromosome 16. Mamm. Genome 6 798-801.
78. N. Janicic, Z. Pausova, D.E.C. Cole and G.N. Hendy (1995) Insertion of an Alu sequence in the Ca2+-sensing receptor gene in familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT). Am. J. Hum. Genet. 56 880-886.
79. S. Jin, H. Mao, R.W. Schnepp, S.M. Sykes, S.M. Silva, A.C. Silva, A.D. D'Andrea and X. Hua (2003) Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 63 4204-4210.
80. C. Juhlin, C. Larsson, T. Yakoleva, I. Leibiger, B. Leibiger, A. Alimov, G. Weber, A. Hoog and A. Villablanca (2006) Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr. Relat. Cancer 13 509-523.
81. C.C. Juhlin, A. Villablanca, K. Sandelin, F. Haglund, J. Nordenström, L. Forsberg, R. Bränström, T. Obara, A. Arnold, C. Larsson and A. Höög (2007) Parafibromin immunoreactivity – its use as an additional diagnostic marker for parathyroid tumour classification. Endocr. Relat. Cancer 14 501-512.
82. H. Kaji, L. Canaff, D. Goltzman and G.N. Hendy (1999) Cell cycle regulation of menin expression. Cancer Res 59 5097-5101.
83. H. Kaji, L. Canaff, J.J. Lebrun, D. Goltzman and G.N. Hendy (2001) Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling. Proc. Natl. Acad. Sci. USA 98 3837-3842.
84. S.K. Karnick, C.M. Hughes, X. Gu, O. Rozenblatt-Rosen, G.W. McLean, Y. Xiong, M. Meyerson and S.K. Kim (2005) Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl. Acad. Sci. USA 102 14659-14664.
85. T.G. Kelly, T.M. Shattuck, M. Reyes-Mugica, A.F. Stewart, W.F. Simonds, R. Udelsman, A. Arnold and T.O. Carpenter (2006) Surveillance for early detection of aggressive parathyroid disease: Carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with germline HRPT2 mutation. J. Bone Miner. Metab. 21 1666-1671.
86. O. Kifor, F.D. Moore, P. Wang, M. Goldstein, P. Vassilev, I. Kifor, S. Hebert and E.M. Brown (1996) Reduced immunostaining for the extracellular Ca2+-receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81 1598-1606.
87. T. Kimura, K. Yoshimoto, C. Tanaka, T. Ohkura, H. Iwahana, A. Miyauchi, T. Sano and M. Itakura (1996) Obvious mRNA and protein expression but absence of mutations of the RET proto-oncogene in parathyroid tumors. Eur. J. Endocrinol. 134 314-319.
88. P. Komminoth, J. Roth, S. Muletta-Feurer, P. Sasemaslani, W.K. Seelentag and P.U. Heitz (1996) RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J. Clin. Endocrinol. Metab. 81 2041-2046.
89. S. Kytola, F. Farnebo, T. Obara, J. Isola, L. Grimelius, L.O. Farnebo, K. Sandelin and C. Larsson (2000) Patterns of chromosomal imbalances in parathyroid carcinomas. Am. J. Pathol. 157 579-586.
90. A. Lacerte, E.H. Lee, R. Reynaud, L. Canaff, C. DeGuise, D. Devost, S. Ali, G.N. Hendy and J.J. Lebrun (2004) Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and Menin. Mol. Endocrinol. 18 1558-1569.
91. C. Larsson, B. Skogseid, K. Oberg, Y. Nakamura and M. Nordenskjold (1988) Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332 85-87.
92. W.M. Law Jr. and H. Heath III (1985) Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenic studies in 21 families. Ann. Intern. Med. 102 511-519.
93. W.M. Law Jr., S.F. Hodgson and H. Heath III (1983) Autosomal recessive inheritance of familial hyperparathyroidism. N. Engl. J. Med. 309 650-653.
94. S.K. Libutti, J.S. Crabtree, D. Lorang, A.L. Burns, C. Mazzanti, S.M. Hewitt, S. O'Connor, J.M. Ward, M.R. Emmert-Buck, A. Remaley, M. Miller, E. Turner, H.R. Alexander, A. Arnold, S.J. Marx, F.S. Collins and A.M. Spiegel (2003) Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res. 63 8022-8028.
95. S.Y. Lin and S.J. Elledge (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113 881-889.
96. L. Lin, M. Czapiga, L. Nini, J.H. Zhang and W.F. Simonds (2007) Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Mol. Cancer Res. 5 183-193.
97. S.M. Mallya, J.J. Gallagher, Y.K. Wild, O. Kifor, J. Costa-Guda, K. Saucier, E.M. Brown and A. Arnold (2005) Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol. Endocrinol. 19 2603-2609.
98. D.J. Marsh, Z. Zheng, A. Arnold, S.D. Andrew, D. Learoyd, A. Frilling, P. Komminoth, H.P. Neumann, B.A. Ponder, B.J. Rollins, G.I. Shapiro, B.G. Robinson, L.M. Mulligan and C. Eng (1997) Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for a RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors. J. Clin. Endocrinol. Metab. 82 3025-3028.
99. S.J. Marx, M.F. Attie, M.A. Levine, A.M. Spiegel, R.W. Downs Jr. and R.D. Lasker (1981) The hypocalciuric or benign variant of familial hypercalcemia: Clinical and biochemical features in fifteen kindreds. Medicine 60 397-412.
100. T.A. Milne, C.M. Hughes, R. Lloyd, Z. Yang, O. Rozenblatt-Rosen, Y. Dou, R.W. Schnepp, C. Krankel, V.A. Livolsi, D. Gibbs, X. Hua, R.G. Roeder, M. Meyerson and J.L. Hess (2005) Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl. Acad. Sci. USA 102 749-754.
101. C. Mosimann, G. Hausmann and K. Basler (2006) Parafibromin/Hydrax activates Wnt/Wg target gene transcription by direct association with β-catenin/Armadillo. Cell 125 327-341.
102. T. Motokura and A. Arnold (1993) PRAD1/cyclin D1 proto-oncogene: Genomic organization, 5'DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chrom. Cancer 7 89-95.
103. T. Motokura, T. Bloom, H.G. Kim, H. Juppner, J.V. Ruderman, H.M. Kronenberg and A. Arnold (1991) A novel cyclin encoded by a bcll-linked candidate oncogene. Nature 350 512-515.
104. J. Naito, H. Kaji, H. Sowa, R. Kitazawa, S. Kitazawa, T. Tsukada, G.N. Hendy, T. Sugimoto and K. Chihara (2006) Expression and functional analysis of menin in a multiple endocrine neoplasia type 1 (MEN1) patient with somatic loss of heterozygosity in chromosome 11q13 and unidentified germline mutation of the MEN1 gene. Endocrine 29 485-490.
105. S.R. Nussbaum, R.D. Gaz and A. Arnold (1990) Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N. Engl. J. Med. 323 1324-1328.
106. C. Orndal, M. Johansson, S. Heim, N. Mandahl, B. Mansson, J. Alumets and F. Mitelman (1990) Parathyroid adenoma with t(1:5)(p22:q32) as the sole clonal chromosomal abnormality. Cancer Genet. Cytogenet. 48 225-228.
107. A. Ozawa, S.K. Agarwal, C.M. Mateo, A.L. Burns, T.S. Rice, P.A. Kennedy, C.M. Quigley, W.F. Simonds, L.S. Weinstein, S.C. Chandrasekharappa, F.S. Collins, A.M. Spiegel and S.J. Marx (2007) The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J. Clin. Endocrinol. Metab. 92 1948-1951.
108. B.C. Padberg, S. Schroder, W. Jochum, H. Kastendieck, J. Roth, P.U. Heitz and P. Komminoth (1995) Absence of RET proto-oncogene point mutations in sporadic and neoplastic lesions of the parathyroid gland. Am. J. Pathol. 147 1539-1544.
109. N. Palanisamy, Y. Imanishi, P.H. Rao, H. Tahara, R.S. Chaganti and A. Arnold (1998) Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J. Clin. Endocrinol. Metab. 83 1766-1770.
110. A.A.J. Pannett, A.M. Kennedy, J.J. Turner, S.A. Forbes, B.M. Cavaco, J.H. Bassett, L. Cianferotti, B. Harding, B. Shine, F. Flinter, C.G. Maidment, R. Trembath and R.V. Thakker (2003) Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin. Endocrinol (Oxf) 58 639-646.
111. A.M. Parfitt (1994) Parathyroid growth, normal and abnormal. J.P. Bilezekian, R. Marcus, M.A. Levine (Eds) The Parathyroids New York: Raven Press 373-405.
112. Z. Pausova, E. Soliman, N. Amizuka, N. Janicic, E.M. Konrad, A. Arnold, D. Goltzman and G.N. Hendy (1995) Expression of the RET proto-oncogene in hyperparathyroid tissues: Implications for the pathogenesis of the parathyroid disease in MEN 2A. J. Bone Miner. Res. 10(Suppl. 1), P249. S191
113. Z. Pausova, E. Soliman, N. Amizuka, N. Janicic, E.M. Konrad, A. Arnold, D. Goltzman and G.N. Hendy (1996) Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 81 2711-2718.
114. S.H.S. Pearce, D. Trump, C. Wooding, M.N. Sheppard, R.N. Clayton and R.V. Thakker (1996) Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin. Endocrinol. 45 195-200.
115. N.S. Pellegata, L. Quintanilla-Martinez, E. Samson, H. Siggelkow, K. Bink, J. Graw, H. Hofler and M.J. Atkinson (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. USA 103 15558-15563.
116. R.G. Pestell, C. Albanese, A.T. Reutens, J.E. Segall, R.J. Lee and A. Arnold (1999) The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr. Rev. 20 501-534.
117. S. Pidasheva, L. Canaff, W.F. Simonds, S.J. Marx and G.N. Hendy (2005) Impaired cotranslational process of the calcium-sensing receptor due to signal peptide missense mutations in familial hypocalciuric hypercalcemia. Hum. Mol. Genet. 14 1679-1690.
118. S. Pidasheva, M. Grant, L. Canaff, O. Ercan, U. Kumar and G.N. Hendy (2006) Calcium-sensing receptor dimerizes in the endoplasmic teticulum: biochemical and biophysical characterization of CASR mutants is retained intracellularly. Hum. Mol. Genet. 15 2200-2209.
119. A. Poisson, B. Zablewska and P. Gaudray (2003) Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett. 189 1-10.
120. M.R. Pollak, E.M. Brown, Y.H.W. Chou, S.C. Hebert, S.J. Marx, B. Steinmann, T. Levi, C.E. Seidman and J.G. Seidman (1993) Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75 1297-1303.
121. M.R. Pollak, Y.H.W. Chou, S.J. Marx, B. Steinmann, D.E.C. Cole, M.L. Brandi, S.E. Papapoulos, F.H. Menko, G.N. Hendy, E.M. Brown, C.E. Seidman and J.G. Seidman (1994) Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J. Clin. Invest. 93 1108-1112.
122. C.L. Rosenberg, H.G. Kim, T.B. Shows, H.M. Kronenberg and A. Arnold (1991) Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene 6 449-453.
123. C.L. Rosenberg, T. Motokura, H.M. Kronenberg and A. Arnold (1993) Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors. Oncogene 8 519-521.
124. O. Rozenblatt-Rosen, C.M. Hughes, S.J. Nannepaga, K.S. Shanmugam, T.D. Copeland, T. Guszczynski, J.H. Resau and M. Meyerson (2005) The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol. Cell Biol. 25 612-620.
125. E.H. Samander and A. Arnold (2006) Mutational analysis of the vitamin D receptor does not support its candidacy as a tumor suppressor gene in parathyroid adenomas. J. Clin. Endocrinol. Metab. 91 5019-5021.
126. S. Semba, R. Kusumi, Moriya and H. Sasano (2000) Nuclear accumulation of β-catenin in human endocrine tumors: Association with Ki-67 (MIB-1) proliferative activity. Endocr. Pathol. 11 243-250.
127. T.H. Shattuck, J. Costa, M. Bernstein, R.T. Jensen, D.C. Chung and A. Arnold (2002) Mutational analysis of Smad3, a candidate tumor suppressor implicated in TGF-β and menin pathways, in parathyroid adenomas and enetropancreatic endocrine tumors. J. Clin. Endocrinol. Metab. 87 3911-3914.
128. T.M. Shattuck, S. Valimaki, T. Obara, R.D. Gaz, O.H. Clark, D. Shoback, M.E. Wierman, K. Tojo, C.M. Robbins, J.D. Carpten, L.O. Farnebo, C. Larsson and A. Arnold (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349 1722-1729.
129. T.M. Shattuck, T.S. Kim, J. Costa, D.W. Yandell, Y. Imanishi, N. Palanisamy, R.D. Gaz, D. Shoback, O.H. Clark, J.M. Monchik, M.E. Wierman, A. Hollenberg, K. Tojo, R.S.K. Chaganti and A. Arnold (2003) Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf). 59 180-189.
130. C.J. Sherr (1996) Cancer cell cycles. Science 274 1672-1677.
131. W.F. Simonds (2007) Ruling out a suspect: The role of β-catenin mutation in benign parathyroid neoplasia [Editorial]. J. Clin. Endocrinol. Metab. 92 1235-1236.
132. W.F. Simonds, L.A. James-Newton, S.K. Agarwal, B. Yang, M.C. Skarulis, G.N. Hendy and S.J. Marx (2002) Familial isolated hyperparathyroidism: Clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 81 1-26.
133. W.F. Simonds, C.M. Robbins, S.K. Agarwal, G.N. Hendy, J.D. Carpten and S.J. Marx (2004) Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J. Clin. Endocrinol. Metab. 89 96-102.
134. Y.L. Soei, M. Karperien, B. Bakker, M.H. Breuning, G.N. Hendy and S.E. Papapoulos (1999) Familial benign hypercalcemia (FBH) with age-associated hypercalciuria and a missense mutation in the calcium-sensing receptor (CaSR) expands the spectrum of the syndrome towards primary hyperparathyroidism. J. Bone Miner. Res. 14s1 SU062. S447
135. H. Sowa, H. Kaji, R. Kitazawa, S. Kitazawa, T. Tsukamoto, S. Yano, L. Canaff, G.N. Hendy, T. Sugimoto and K. Chihara (2004) Menin inactivation leads to loss of TGF-β inhibition of parathyroid cell proliferation and PTH secretion. Cancer Res. 64 2222-2228.
136. K.E. Sukhodolets, A.B. Hickman, S.K. Agarwal, M.V. Sukhodelets, V.H. Obungu, E.A. Novotny, J.S. Crabtree, S.C. Chandrasekhrappa, F.S. Collins, A.M. Spiegel, A.L. Burns and S.J. Marx (2003) The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol. Cell. Biol. 23 493-509.
137. K. Suphapeetiporn, J.M. Greally, D. Walpita, T. Ashley and A.E. Bale (2002) MEN1 tumor-suppressor protein localizes to telomeres during meiosis. Gene Chromosome Cancer 35 81-85.
138. J. Szabo, B. Heath, V.M. Hill, C.E. Jackson, R.J. Zarbo, L.E. Mallette, S.L. Chew, G.M. Besser, R.V. Thakker, V. Huff, M.F. Leppert and H. Heath III (1995) Hereditary hyperparathyroidism-jaw syndrome: The endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am. J. Hum. Genet. 56 944-950.
139. H. Tahara, A.P. Smith, R.D. Gaz, V.L. Cryns and A. Arnold (1996) Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res. 56 599-605.
140. H. Tahara, A.P. Smith, R.D. Gaz and A. Arnold (1996) Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. J. Clin. Endocrinol. Metab. 81 3663-3667.
141. H. Tahara, A.P. Smith, R.D. Gaz, M. Zariwala, Y. Xiong and A. Arnold (1997) Parathyroid tumor suppressor on 1p: Analysis of the p18 cyclin-dependent kinase inhibitor gene as a candidate. J. Bone Miner. Res. 12 1330-1334.
142. M.H. Tan, C. Morrison, P. Wang, X. Yang, C.J. Haven, C. Zhang, P. Zhao, M.S. Tretiakova, F. Korpi-Hvovalti, J.R. Burgess, K.C. Soo, W.K. Cheah, B. Cao, J. Resau, H. Morreau and B.T. Teh (2004) Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin. Cancer Res. 10 6629-6637.
143. R.V. Thakker, P. Bouloux, C. Wooding, K. Chotal, P.M. Broad, N.K. Spurr, G.M. Besser and J.L.H. O'Riordan (1989) Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N. Engl. J. Med. 321 218-224.
144. D.B. Thompson, W.S. Samowitz, S. Odelberg, R.K. Davis, J. Szabo and H. Heath III (1995) Genetic abnormalities in sporadic parathyroid adenomas: Loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus. J. Clin. Endocr. Metab. 80 3377-3380.
145. Y. Tominaga, T. Tsuzuki, K. Uchida, T. Haba, S. Otsuka, I. Ichimori, K. Yamada, M. Numano, Y. Tanaka and H. Takagi (1999) Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int. 55 1375-1383.
146. J.W. Vaandrager, E. Schuuring, E. Zwikstra, C.J. de Boer, K.K. Kleiverda, J.H. van Krieken, H.C. Kluin-Nelemans, G.J. van Ommen, A.K. Raap and P.M. Kluin (1996) Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 15 1177-1182.
147. J.W. Vaandrager, P. Kluin and E. Schuuring (1997) The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330kb centromeric from the cyclin D1 gene. Blood 89 349-350.
148. J.N. VanHouten, N. Yu, D. Rimm, J. Dotto, A. Arnold, J.J. Wysolmerski and R. Udelsman (2006) Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J. Clin. Endocrinol. Metab. 91 580-583.
149. M.A. Vasef, R.K. Brynes, M. Sturm, C. Bromley and R.A. Robinson (1999) Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: A paraffin immunohistochemical study. Mol. Pathol. 12 412-416.
150. T.J. Vasicek, B.E. McDevitt, M.W. Freeman, B.J. Fennick, G.N. Hendy, J.T. Potts Jr., A. Rich and H.M. Kronenberg (1983) Nucleotide sequence of the human parathyroid hormone gene. Proc. Natl. Acad. Sci. USA 80 2127-2131.
151. A. Villablanca, A. Calendar, L. Forsberg, A. Hoog, J.-D. Cheng, D. Petillo, C. Bauters, K. Kahnoski, T. Ebeling, P. Salmela, A.-L. Richardson, L. Delbridge, A. Meyrier, C. Proye, J.D. Carpten, B.T. Teh, B.G. Robinson and C. Larsson (2004) Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism. J. Med. Genet. 41 e32.
152. B. Vogelstein and K.W. Kinzler (2004) Cancer genes and the pathways they control. Nat. Med. 10 789-799.
153. J. Warner, M. Epstein, A. Sweet, D. Singh, J. Burgess, S. Stranks, P. Hill, D. Perry-Keene, D. Learoyd, B. Robinson, P. Birdsey, E. Mackenzie, B.T. Teh, J.B. Prins and J. Cardinal (2004) Genetic testing in familial hyperparathyroidism: Unexpected results and their implications. J. Med. Genet. 41 155-160.
154. J. Warner, D.R. Nyholt, F. Busfield, M. Epstein, J. Burgess, S. Stranks, P. Hill, D. Perry-Keene, D. Learoyd, B. Robinson, B.T. Teh, J.B. Prins and J.W. Cardinal (2006) Familial isolated hyperparathyroidism is linked to a 1.7Mb region on chromosome 2p13.3-14. J. Med. Genet. 43 e12.
155. L.S. Weinstein and W.F. Simonds (2003) HRPT2, a marker of parathyroid carcinoma. N. Engl. J. Med. 349 1691-1692.
156. M.E. Williams, S.H. Swerdlow, C.L. Rosenberg and A. Arnold (1993) Chromosome 11 translocation breakpoints at the PRAD1 cyclin gene locus in centrocytic lymphoma. Leukemia 7 241-245.
157. G.H. Williams, S. Rooney, A. Carss, G. Cummins, G.A. Thomas and E.D. Williams (1996) Analysis of the RET proto-oncogene in sporadic parathyroid adenomas. J. Pathol. 180 138-141.
158. C. Williamson, A.J. Pannett, J.T. Pang, C. Wooding, M. McCarthy, M.N. Sheppard, J.P. Monson, R.N. Clayton and R.V. Thakker (1997) Localization of a gene causing endocrine neoplasia to a 4cM region on chromosome 1p35-p36. J. Med. Genet. 34 617-619.
159. G.E. Woodward, L. Lin, J.H. Zhang, S.K. Agarwal, S.J. Marx and W.F. Simonds (2004) Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expresssion. Oncogene 24 1272-1276.
160. A. Yart, M. Gstaiger, C. Wirbelauer, M. Pecnik, D. Anastasiou, D. Hess and W. Krek (2005) The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol. Cell. Biol. 25 5052-5060.
161. H. Yaguchi, N. Ohkura, M. Takahashi, Y. Nagamura, I. Kitabayashi and T. Tsukada (2004) Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol. Cell. Biol. 24 6569-6580.
162. A. Yokoyama, Z. Wang, J. Wysocka, M. Sanval, D.J. Aufiero, I. Kitabayashi, W. Herr and M.L. Cleary (2004) Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell Biol. 24 5639-5649.
163. K. Yoshimoto, H. Iwahana, A. Fukuda, T. Sano, S. Saito and M. Itakura (1992) Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res. 52 5061-5064.
164. K. Zajickova, J. Vrbikova, L. Canaff, P.D. Pawelek, D. Goltzman and G.N. Hendy (2007) Identification and functional characterization of a novel mutation in the calcium-sensing receptor gene in familial hypocalciuric hypercalcemia: Modulation of clinical severity by vitamin D status. J. Clin. Endocrinol. Metab. 92 2616-2623.
165. C. Zhang, D. Kong, M.H. Tan, D.L. Pappas Jr., P.F. Wang, J. Chen, L. Farber, N. Zhang, H.M. Koo, M. Weinreich, B.O. Williams and B.T. Teh (2006) Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem. Biophys. Res. Commun. 350 17-24.